Stay updated on Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed. Additionally, a significant piece of information regarding the modernization of ClinicalTrials.gov data ingest in July 2025 has been deleted.
    Difference
    0.5%
    Check dated 2025-07-04T04:28:22.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    19 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.4%
    Check dated 2025-06-19T20:12:52.000Z thumbnail image
  4. Check
    26 days ago
    No Change Detected
  5. Check
    33 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.0%
    Check dated 2025-06-05T11:24:10.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    0.7%
    Check dated 2025-05-29T06:17:52.000Z thumbnail image
  7. Check
    69 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.0%
    Check dated 2025-04-30T18:09:46.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    The page has removed significant details about a Phase 1b study evaluating lenvatinib and pembrolizumab for hepatocellular carcinoma, including the study's design, objectives, and inclusion/exclusion criteria, while adding a new identifier and revision number.
    Difference
    7%
    Check dated 2025-04-16T13:12:02.000Z thumbnail image

Stay in the know with updates to Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma Clinical Trial page.